Low-dose aspirin as treatment for central serous chorioretinopathy

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 899-903

  Caccavale, Antonio ^a   Romanazzi, Filippo ^a   Imparato, Manuela ^a   Negri, Angelo ^a   Morano, Anna ^b   Ferentini, Fabio ^a  

^a Department of Ophthalmology   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Aspirin; Central serous chorioretinopathy; Macula; Plasminogen activator inhibitor 1

Indexed keywords

EID: 77956126391     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/opth.s12583     Document Type: Article

References (39)

1. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231-242.
2. Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous retinopathy. Am J Ophthalmol. 1996;121(1):26-34.
3. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999;19(6):508-512.
4. Okushiba U, Takeda M. Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography. Nippon Ganka Gakkai Zasshi. 1997;101(1):74-82.
5. Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol. 2003;87(6):709-712.
6. Hirami Y, Tsujikawa A, Sasahara M, et al. Alterations of retinal pigment epithelium in central serous chorioretinopathy. Clin Exp Ophthalmol. 2007;35(3):225-230.
7. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1): 63-68.
8. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: A case-control study. Ophthalmology. 2004;111(2): 244-249.
9. Schultz KL, Birnbaum AD, Goldstein DA. Ocular disease in pregnancy. Curr Opin Ophthalmol. 2005;16(5):308-314.
10. Hussain D, Gass JD. Idiopathic central serous chorioretinopathy. Indian J Ophthalmol. 1998;46(3):131-137.
11. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987;7(2):111-131.
12. Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962-964.
13. Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993; 111(9):1229-1233.
14. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110(4): 689-703.
15. Tewari HK, Gadia R, Kumar D, et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy. Invest Ophth Vis Sci. 2006;47(8):3474-3478.
16. Moon SJ, Mieler WF. Retinal complication of bone marrow and solid organ transplantation. Curr Opin Ophthalmol. 2003;14(6): 433-442.
17. Kian-Ersi F, Taheri S, Akhlaghi MR. Ocular disorders in renal transplant patients. Saudi J Kidney Dis Transpl. 2008;19(5):751-755.
18. Shah VA, Randhawa S, Boldt HC, Lee AG. Central serous chorioretinopathy in giant cell arteritis. Semin Ophthalmol. 2006;21(1):45-48.
19. Cunningham ET Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996;103(12):2081-2090.
20. Kaneko E, Nawano M, Honda N, et al. Ulcerative colitis complicated by idiopathic central serous chorioretinopathy with bullous retinal detachment. Dig Dis Sci. 1985;30(9):896-900.
21. Schreiber JB, Lakhanpal V, Nasrallah SM. Crohn's disease complicated by idiopathic central serous chorioretinopathy with bullous retinal detachment. Dig Dis Sci. 1989;34(1):118-122.
22. Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993; 111(9):1229-1233.
23. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431-448.
24. Chaine G, Haouat M, Menard-Molcard C, et al. Central serous chorioretinopathy and systemic steroid therapy. J Fr Ophtalmol. 2001; 24(2):217-221. French.
25. Pecora JL. Ibuprofen in the treatment of central serous chorioretinopathy. Ann Ophthalmol. 1978;10(11):1481-1483.
26. Yamada R, Yamada S, Ishii A, Tane S. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi. 1993;97(8):955-960.
27. Iijima H, Iida T, Murayama K, et al. Plasminogen activator inhibitor-1 in central serous chorioretinopathy. Am J Ophthalmol. 1999;127(4): 477-478.
28. Caccavale A, Imparato M, Romanazzi F, Negri A, et al. A new strategy of tretment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses. 2009;73(3):435-437.
29. Mitchell GC, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68:815-820.
30. Brancato R, Scialdone A, Pece A, et al. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol. 1987;225:166-168.
31. Bujarboua D. Long-term follow up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand. 2001;79:417-421.
32. Loo RH, Scott IU, Flynn HW Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19-24.
33. Sibilia J, Ravaud P, Marck G. Digestive and hemorrhage complications of low-dose aspirin. Presse Med. 2003;32(37 Pt 2):S17-S28.
34. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126-145.
35. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: A prospective, controlled clinical study. Curr Eye Res. 2010;35(2):91-98.
36. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009;19(4):613-617.
37. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010;24(3):155-158.
38. Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007;27(7):943-946.
39. Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: A pilot study. Acta Ophthalmol. 2009 May 12. [Epub ahead of print].